| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 143, Issue 10 3222-3229, Copyright © 1989 by American Association of Immunologists
ARTICLES |
S Bodmer, K Strommer, K Frei, C Siepl, N de Tribolet, I Heid and A Fontana
Department of Internal Medicine, University Hospital, Zurich, Switzerland.
Transforming growth factor (TGF)-beta 1 is a polypeptide that is assumed to play a fundamental role in the growth of both normal and neoplastic cells. TGF-beta 2 is a closely related polypeptide, originally described as glioblastoma cell-derived T cell suppressor factor (G-TsF) due to its immunosuppressive activity. Expression of the genes for TGF-beta 1 and G-TsF/TGF-beta 2 was examined in tumor cells and was found to be different in several cell lines and tissues that were tested. Whereas two glioblastoma cell lines expressed both TGF- beta 1 and G-TsF/TGF-beta 2 mRNA, one melanoma and neuroblastoma cell lines showed only TGF-beta 1 mRNA which in the case of the neuroblastoma required cycloheximide treatment for its detection. The coordinate expression of the genes for TGF-beta 1 and G-TsF/TGF-beta 2 in glioblastoma was not paralleled by secretion of both polypeptides as only G-TsF/TGF-beta 2 but not TGF-beta 1 was identified in supernatants of glioblastoma cells. These data provide evidence for a post- transcriptional level of regulation for production of the two forms of TGF-beta. As mRNA for G-TsF/TGF-beta 2 was also identified in fresh surgically removed human glioblastoma tissue, G-TsF/TGF-beta 2 may also be secreted within the tumor in vivo. Unlike glioblastoma, human fetal brain tissues or adult brain specimens studied did not express detectable levels of TGF-beta mRNA. Impaired cell-mediated immunity is an established finding in patients with glioblastoma. Secretion of G- TsF/TGF-beta 2 by tumor cells in vivo may contribute to decreased immune surveillance for tumor development, as well as neovascularization of the tumor tissue.
This article has been cited by other articles:
|
|
 |
|
  Y. Shintani, M. Maeda, N. Chaika, K. R. Johnson, and M. J. Wheelock Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor Signaling Am. J. Respir. Cell Mol. Biol., January 1, 2008; 38(1): 95 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-T. Tran, M. Uhl, J. Y. Ma, L. Janssen, V. Sriram, S. Aulwurm, I. Kerr, A. Lam, H. K. Webb, A. M. Kapoun, et al. Inhibiting TGF-{beta} signaling restores immune surveillance in the SMA-560 glioma model Neuro-oncol, July 1, 2007; 9(3): 259 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nemunaitis, R. O. Dillman, P. O. Schwarzenberger, N. Senzer, C. Cunningham, J. Cutler, A. Tong, P. Kumar, B. Pappen, C. Hamilton, et al. Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non-Small-Cell Lung Cancer J. Clin. Oncol., October 10, 2006; 24(29): 4721 - 4730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer, A. Steinle, M. Weller, and M. A. Friese TGF-{beta} and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells Brain, September 1, 2006; 129(9): 2416 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ali, G. D. King, J. F. Curtin, M. Candolfi, W. Xiong, C. Liu, M. Puntel, Q. Cheng, J. Prieto, A. Ribas, et al. Combined Immunostimulation and Conditional Cytotoxic Gene Therapy Provide Long-term Survival in a Large Glioma Model Cancer Res., August 15, 2005; 65(16): 7194 - 7204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tang, P. Flomenberg, L. Harshyne, L. Kenyon, and D. W. Andrews Glioblastoma Patients Exhibit Circulating Tumor-Specific CD8+ T Cells Clin. Cancer Res., July 15, 2005; 11(14): 5292 - 5299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chahlavi, P. Rayman, A. L. Richmond, K. Biswas, R. Zhang, M. Vogelbaum, C. Tannenbaum, G. Barnett, and J. H. Finke Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70 Cancer Res., June 15, 2005; 65(12): 5428 - 5438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Elliott and G. C. Blobe Role of Transforming Growth Factor Beta in Human Cancer J. Clin. Oncol., March 20, 2005; 23(9): 2078 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Friese, J. Wischhusen, W. Wick, M. Weiler, G. Eisele, A. Steinle, and M. Weller RNA Interference Targeting Transforming Growth Factor-{beta} Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo Cancer Res., October 15, 2004; 64(20): 7596 - 7603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Godard, G. Getz, M. Delorenzi, P. Farmer, H. Kobayashi, I. Desbaillets, M. Nozaki, A.-C. Diserens, M.-F. Hamou, P.-Y. Dietrich, et al. Classification of Human Astrocytic Gliomas on the Basis of Gene Expression: A Correlated Group of Genes with Angiogenic Activity Emerges As a Strong Predictor of Subtypes Cancer Res., October 15, 2003; 63(20): 6613 - 6625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Beatty and Y. Paterson IFN-{{gamma}}-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-{{gamma}} J. Immunol., February 15, 2001; 166(4): 2276 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Beatty and Y. Paterson IFN-{gamma} Can Promote Tumor Evasion of the Immune System In Vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen J. Immunol., November 15, 2000; 165(10): 5502 - 5508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. X. Zhu, S. Sharma, M. Stolina, B. Gardner, M. D. Roth, D. P. Tashkin, and S. M. Dubinett {Delta}-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway J. Immunol., July 1, 2000; 165(1): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Carpentier, J. Xie, K. Mokhtari, and J.-Y. Delattre Successful Treatment of Intracranial Gliomas in Rat by Oligodeoxynucleotides Containing CpG Motifs Clin. Cancer Res., June 1, 2000; 6(6): 2469 - 2473. [Abstract] [Full Text]
|
|
|
|
 |
|
 A.G.S. Buggins, N. Lea, J. Gaken, D. Darling, F. Farzaneh, G.J. Mufti, and W.J.R. Hirst Effect of Costimulation and the Microenvironment on Antigen Presentation by Leukemic Cells Blood, November 15, 1999; 94(10): 3479 - 3490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Zou, L. A. Morford, C. Chougnet, A. R. Dix, A. G. Brooks, N. Torres, J. D. Shuman, J. E. Coligan, W. H. Brooks, T. L. Roszman, et al. Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) That Alters Monocyte Cytokine Profile and Surface Markers J. Immunol., April 15, 1999; 162(8): 4882 - 4892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D O Pena, A. W Taylor, C. S Ricard, I. Vidal, and M R. Hernandez Transforming growth factor beta isoforms in human optic nerve heads Br. J. Ophthalmol., February 1, 1999; 83(2): 209 - 218. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Genestier, S. Kasibhatla, T. Brunner, and D. R. Green Transforming Growth Factor beta 1 Inhibits Fas Ligand Expression and Subsequent Activation-induced Cell Death in T Cells via Downregulation of c-Myc J. Exp. Med., January 18, 1999; 189(2): 231 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Sampson THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif. Neuro-oncol, January 1, 1999; 1(1): 33 - 42. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
